Cleveland ClinicCleveland, Ohio, United States
Disclosure information not submitted.
Paper 82 - PHASE I/II STUDY OF THE TGF-BETA-TRAP ENHANCED ONCOLYTIC ADENOVIRUS, ADAPT-001, WITH AND WITHOUT AN IMMUNE CHECKPOINT INHIBITOR FOR SARCOMA PATIENTS
Saturday, November 16, 202410:30 AM – 12:00 PM PST